Although most clinical studies suggested that sphingomyelins and phosphatidylcholines, such as C32:2, C34:1, and C34:2, are associated with reduced insulin sensitivity in humans [32,33], a metabolomic analysis in newly developed type 2 diabetes subjects shows that some phosphatidylcholines, are significantly associated with decreased risk of diabetes [33,34]. This evidence concerns the gene INS and type 2 diabetes mellitus.